These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2760157)

  • 1. Application of analytical isotachophoresis in the study of platelet membrane proteins in patients with chronic myeloproliferative disorders.
    Kajii E; Ikemoto S
    J Chromatogr; 1989 May; 490(1):53-8. PubMed ID: 2760157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
    Cooper B; Ahern D
    J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A; Südhoff T; Meierkord F
    Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
    Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
    Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet defects in chronic myeloproliferative disorders].
    Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
    Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
    Yamamoto K; Sekiguchi E; Takatani O
    Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets in the myeloproliferative syndrome.
    Weinfeld A; Branehög I; Kutti J
    Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
    Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
    Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
    Moliterno AR; Hankins WD; Spivak JL
    N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ATP and ADP of platelets in chronic myeloproliferative disorders and multiple myeloma].
    Terada H; Ohshima M
    Rinsho Ketsueki; 1989 Jan; 30(1):22-8. PubMed ID: 2716195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests.
    Boneu B; Nouvel C; Sie P; Caranobe C; Combes D; Laurent G; Pris J; Bierme R
    Scand J Haematol; 1980 Sep; 25(3):214-20. PubMed ID: 7466310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospholipid determination in platelets, plasma and red cells of patients with chronic myeloproliferative disorders.
    Cesar JM; Vecino A; Perez-Vaquero M; Navarro JL
    Eur J Haematol; 1993 Apr; 50(4):234-6. PubMed ID: 8500606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.